By Manas Mishra and Sriparna Roy (Reuters) -Biogen on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off slowly, but said the[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
